Update: PBS listing of adalimumab for hidradentis suppurativa

Update: PBS listing of adalimumab for hidradentis suppurativa

Adalimumab (Humira) is now listed on the Phamaceutical Benefits Scheme (PBS) for treatment of patients with moderate to severe hidradenitis suppurativa.

Clinical criteria include Hurley stage II or III grading with an abscess and inflammatory nodule count greater than or equal to three and failure, adverse reaction or contraindication to antibiotics (two courses of different antibiotics each for three months). Patients must be treated by a dermatologist.

For more information, visit the PBS website.